

TRANSFORMING MS 4 ALL (TMS4ALL); RECENT ACHIEVEMENTS AND PROGRESS

Joela Mathews¹ David Rog², Sian McKay³ and Jeremy Hobart⁴

¹Barts Health, London ²Manchester Centre for Clinical Neurosciences, ³Stratified Medicine, Glasgow, ⁴University of Plymouth, UK

Introduction

Transforming MS for All (TMS4All) is a not for profit, multidisciplinary UK community dedicated to improve MS services and outcomes by addressing challenges our audit identified¹.

Aims

To update ABN attendees on TMS4All's progress.

Methods

Review TMS4All's recent activity.

Results / Outputs

In 2023 TMS4All;

- Designed, developed and launched a password protected website (www.TransformingMSForAll.org) for all UK MS HCPs, providing a service map, good practice document repository and event information.
- Held a **national summit** (attendance >80 delegates), which identified key issues, including;
 - Advancing Clinical trial opportunities by;
 - Clarifying what pharma needs;
 - Recommending job plans that attract and retaining principal investigators
 - quantifying NHS savings from DMT trials
 - The need for;
 - post CCT MS fellowships for succession planning
 - standardised clinic documentation and MS care practices
 - administrative roles enhancing strategic and operational clinical data usage
- Held a **post summit Q&A webinar** with an ICS chair and NHSE Clinical Adviser (chaired by ABN president elect) attended by 46 delegates).
- Collaborated with NHSE on **adult neurology and MS DMT dashboard development**.
- Completed the **patient expectation framework project literature search**.
- Presented work **raising awareness nationally² and internationally³**.

Conclusion:

TMS4All has evolved into an MS service development focal point, by effective partnership working with multiple stakeholders.

References

1 Hobart J, Mathews J, Rog DJ. MSJ 2021; 27: (2S) 305. 2 Rog DJ. Presentation to MS Specialist Interest Group (SIG). ABN Belfast May 2023. 3 Mathews J, Rog D, Hobart J, Mckay S, Dougan, Transforming MS 4 All Collaborative. MSJ 2023;29:(3S) P1212/962.

Acknowledgements

The authors wish to acknowledge the members of the UK MS community who have contributed to the audit and the website Chris Smith and Medicodigital [www.medicodigital.co.uk] for developing the website Biogen, Janssen, Novartis, Merck, Sanofi and Roche have contributed to the TMS4All initiative. None of these companies have had input into the content

